Figure 3.

Response to mobocertinib in patients with EGFRex20ins mutations treated at 160 mg daily (n=28). A. Best percentage change from baseline in target lesions by molecular subtype. Mutations by patient are shown under the figure. B. Plot showing objective responses by time on treatment and baseline CNS metastases status. Three patients were excluded from these plots: 1 patient had nonmeasurable baseline target lesions, and 2 patients had no follow-up scans.

Abbreviations: CNS, central nervous system, EGFRex20ins, epidermal growth factor receptor gene exon 20 insertion; IO, immune-oncology therapy; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.

^a Active brain metastases were either never treated or progressed after radiation.